DESCOVY® had less long-term impact on markers of renal function vs FTC/TDF1,2
Median change in eGFRCG through Week 96
There was a 4.1 mL/min difference between DESCOVY FOR PrEP® (+3.7 mL/min) and FTC/TDF (-0.4 mL/min) in eGFRCG at Week 96.2
The long-term clinical significance of changes in eGFR is not known.
Lower serum creatinine levels were also seen with DESCOVY FOR PrEP® through Week 96
- Median serum creatinine decreased 0.02 mg/dL with DESCOVY FOR PrEP vs a 0.01 mg/dL decrease with FTC/TDF from baseline at Week 96
- DESCOVY FOR PrEP can be used in people with impaired renal function of CrCl ≥30 mL/min
eGFR remained steady over 144 weeks with DESCOVY®2,3
Analysis of eGFR from baseline to ≥144 weeks (DESCOVY)
Median change in eGFR
The long-term clinical significance of changes in eGFR is not known.
DESCOVY® had less long-term impact on eGFR in participants ≥50 years of age2,4
Results were seen in participants of an age group that may already be experiencing age-associated declines
Median change in eGFRCG in participants ≥50 years of age through Week 96
There was a 4.4 mL/min difference between DESCOVY FOR PrEP® (+1.2 mL/min) and FTC/TDF (-3.2 mL/min) in eGFRCG at Week 96.4
The long-term clinical significance of changes in eGFR is not known.
DESCOVY FOR PrEP® can be used in people with impaired renal function of
CrCl ≥30 mL/min.2
You may also be interested in:
CrCl=creatinine clearance; eGFRCG=estimated glomerular filtration rate (Cockcroft-Gault); FTC/TDF=emtricitabine/tenofovir disoproxil fumarate; PrEP=pre-exposure prophylaxis; Q1, Q3=first quartile, third quartile.
